Applied Therapeutics (NASDAQ:APLT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The firm presently has a $1.50 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 7.91% from the company’s … Read more
Bowlero (NYSE:BOWL – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The brokerage currently has a $12.00 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 15.50% from the company’s previous close. … Read more
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company … Read more
York Water (NASDAQ:YORW – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “The York Water Company impounds, purifies and distributes water. They are regulated by the Pennsylvania Public Utility Commission in … Read more
NuCana (NASDAQ:NCNA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a $0.75 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 11.44% from the company’s current … Read more
Hepion Pharmaceuticals (NASDAQ:HEPA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from … Read more
MEI Pharma (NASDAQ:MEIP – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is … Read more
European Wax Center (NASDAQ:EWCZ – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm presently has a $27.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 2.23% from … Read more
Asana (NYSE:ASAN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Asana Inc. provides work management platform as software as service which enables individuals and teams to get work done. Asana Inc. is based … Read more
Hess (NYSE:HES – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. They presently have a $134.00 price target on the oil and gas producer’s stock. Zacks Investment Research‘s price target would indicate a potential … Read more